Table 2 Patient Stratification by Gender
| Â | # of Patients (%) | ||
|---|---|---|---|
Characteristic | Female | Male | P Value |
Age (yrs) (n = 86) | Â | Â | 0.26 |
   <60 | 37 (88.1%) | 42 (95.5%) |  |
   >/=60 | 5 (11.9%) | 2 (4.5%) |  |
Ethnicity (n = 87) | Â | Â | 0.19 |
   Hispanic | 23 (53.5%) | 30 (68.2%) |  |
   Non-Hispanic | 20 (46.5%) | 14 (31.8%) |  |
Hemoglobin (g/dL) (n = 83) | Â | Â | 0.019 |
   <12 | 34 (80.9%) | 23 (56.1%) |  |
   >/=12 | 8 (19.1%) | 18(43.9%) |  |
Leukocyte count (× 109/L) (n = 85) |  |  | 0.46 |
   <50 | 13 (30.2%) | 9 (21.4%) |  |
   >/=50 | 30 (69.8%) | 33 (78.6%) |  |
Platelets (× 109/L) (n = 82) |  |  | 0.041 |
   <450 | 20 (48.8%) | 30 (73.2%) |  |
   >/=450 | 21 (51.2%) | 11 (26.8%) |  |
Hasford Score (n = 64) | Â | Â | 1 |
   </=780 low-risk | 19 (52.8%) | 16 (57.1%) |  |
   >780 and </=1480 intermediate | 12 (33.3%) | 9 (32.1%) |  |
   >1480 high-risk | 5 (13.9%) | 3 (10.7%) |  |
Sokal Score (n = 65) | Â | Â | 0.39 |
   <0.8 good prognosis | 12 (33.3%) | 13 (44.8%) |  |
   0.8–1.2 moderate prognosis | 16 (44.4%) | 8 (27.6%) |  |
   >1.2 poor prognosis | 8 (22.2%) | 8 (27.6%) |  |
CHR at 3 months, all treatments (n = 47) | Â | Â | 0.23 |
   Yes | 13 (50%) | 15 (71.4%) |  |
   No | 13 (50%) | 6 (28.6%) |  |
CHR at 3 months, imatinib only (n = 36) | Â | Â | 0.13 |
   Yes | 12 (63.2%) | 15 (88.2%) |  |
   No | 7 (38.4%) | 2 (11.8%) |  |